Goldman Sachs
OREX

Goldman Sachs’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Goldman Sachs’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,336
Closed -$37K – 6979
2017
Q3 		$37K Sell
17,336
-75
-0.4% -$183 ﹤0.01% 6327
2017
Q2 		$50K Sell
17,411
-18,380
-51% -$55.1K ﹤0.01% 6361
2017
Q1 		$123K Sell
35,791
-16,594
-32% -$65.5K ﹤0.01% 5971
2016
Q4 		$91K Buy
52,385
+18,328
+54% +$43.1K ﹤0.01% 6186
2016
Q3 		$113K Sell
34,057
-8,159
-19% -$30.8K ﹤0.01% 6170
2016
Q2 		$182K Sell
42,216
-14,134
-25% -$63.9K ﹤0.01% 5772
2016
Q1 		$317K Sell
56,350
-4,523
-7% -$58.7K ﹤0.01% 5224
2015
Q4 		$1.05M Sell
60,873
-18,881
-24% -$450K ﹤0.01% 4249
2015
Q3 		$1.68M Sell
79,754
-3,141
-4% -$108K ﹤0.01% 3971
2015
Q2 		$4.1M Buy
82,895
+57,886
+231% +$3.46M ﹤0.01% 3137
2015
Q1 		$1.96M Sell
25,009
-44,080
-64% -$2.73M ﹤0.01% 3794
2014
Q4 		$4.19M Sell
69,089
-36,460
-35% -$1.83M ﹤0.01% 3166
2014
Q3 		$4.5M Buy
105,549
+82,004
+348% +$4.4M ﹤0.01% 3123
2014
Q2 		$1.46M Buy
23,545
+17,721
+304% +$1.03M ﹤0.01% 4329
2014
Q1 		$378K Sell
5,824
-4,403
-43% -$298K ﹤0.01% 5539
2013
Q4 		$576K Sell
10,227
-42,958
-81% -$2.41M ﹤0.01% 5193
2013
Q3 		$3.26M Buy
53,185
+45,032
+552% +$3.05M ﹤0.01% 3409
2013
Q2 		$477K Buy
+8,153
New +$502K ﹤0.01% 4979

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs's OREX Position: Q4 2017 in Review

Goldman Sachs sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2017, closing a stake of 17,336 shares — an estimated $37K sold.

Goldman Sachs first reported a position in OREX in Q2 2013 and held it in 18 quarters. The position peaked at $4.5M in Q3 2014. 41 funds tracked by Wall St. Rank hold OREX as of Q4 2017.

  • Goldman Sachs reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Goldman Sachs sold 17,336 Orexigen Therapeutics, Inc. shares in Q4 2017, an estimated $37K.
  • Goldman Sachs first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
  • Goldman Sachs's Orexigen Therapeutics, Inc. position peaked at $4.5M in Q3 2014.
  • 41 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2017.

Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.